Perioperative NSCLC

 OPDIVO® (nivolumab) logo

Selected safety profile

INDICATION OPDIVO® (nivolumab), in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by single-agent OPDIVO as adjuvant treatment after surgery.

CHECKMATE 77T: NEOADJUVANT OPDIVO + CHEMO FOLLOWED BY ADJUVANT OPDIVO AFTER SURGERY

Perioperative OPDIVO: a well-known safety profile with no new safety signals observed at the 41-month median follow-up1,2

Checkmate 77T most serious, most common, and surgery-related adverse reactions (ARs)
 Drip bag icon
Treatment Modifications

See recommended dosing modifications for immune-mediated adverse reactions.

Alt text
Dosing Schedules

Find dosing information to get patients started on therapy. 

Lung icon
More NSCLC Indications

See selected safety profiles for other non-small cell lung cancer indications.

References:

  1. OPDIVO [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
  2. Cascone T, Awad MM, Spicer JD, et al. Perioperative nivolumab vs placebo in patients with resectable NSCLC: updated survival and biomarker analyses from CheckMate 77T. Oral presentation at ASCO 2025. Abstract LBA8010.
  3. Data on file. BMS-REF-NIVO-0293. Princeton, NJ: Bristol-Myers Squibb Company; 2024.


466-US-2500115 06/25